Ipsen SA (id:10608 IPN)
109.30 EUR
Opening hours: 09:00 - 17:30 (Central European Standard Time: 11/27/2024 1:39:57 PM)
Exchange open, closes in 3 hours 50 minutes
About Ipsen SA
Market Capitalization 9.11B
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.
| Headquarters (address) |
65, quai Georges Gorse Boulogne-Billancourt 92100 France |
| Phone | 33 1 58 33 50 00 |
| Website | https://www.ipsen.com |
| Employees | 5,325 |
| Sector | Healthcare |
| Industry | Drug Manufacturers Specialty & Generic |
| Ticker | IPN |
| Exchange | European Stock Exchange |
| Currency | EUR |
| 52 week range | 99.70 - 126.70 |
| Market Capitalization | 9.11B |
| Dividend yield forward | 4.31 % |
| Dividend yield forward France (ID:70, base:257) | 16.26 % |
| P/E trailing | 13.85 |
| P/E forward | 10.87 |
| Price/Sale | 2.65 |
| Price/Book | 2.25 |
| Beta | 0.575 |
| EPS | 7.95 |
| EPS France (ID:70, base:331) | -1.54 |
Forward Annual Dividend Yield
Forward Annual Dividend Yield: Ipsen SA has raised their dividend 4.31 years in a row. This is below the 41466.164200 year average in the 'Drug Manufacturers Specialty & Generic' industry
Compound Average Growth Rate 3 Years
Compound Average Growth Rate 3 Years: Ipsen SA has raised their dividend 6.27 years in a row. This is below the 24.033000 year average in the 'Drug Manufacturers Specialty & Generic' industry
Compound Average Growth Rate 5 Years
Compound Average Growth Rate 5 Years: Ipsen SA has raised their dividend 3.71 years in a row. This is below the 12.576000 year average in the 'Drug Manufacturers Specialty & Generic' industry
Compound Average Growth Rate 10 Years
Compound Average Growth Rate 10 Years: Ipsen SA has raised their dividend 4.14 years in a row. This is below the 10.158800 year average in the 'Drug Manufacturers Specialty & Generic' industry
Payout Ratio
Payout Ratio: Ipsen SA has raised their dividend 15.09 years in a row. This is below the 147.849600 year average in the 'Drug Manufacturers Specialty & Generic' industry
Forward Annual Dividend Yield
Forward Annual Dividend Yield: Ipsen SA has raised their dividend 4.31 years in a row. This is below the 41466.164200 year average in the 'Drug Manufacturers Specialty & Generic' industry
Compound Average Growth Rate 3 Years
Compound Average Growth Rate 3 Years: Ipsen SA has raised their dividend 6.27 years in a row. This is below the 24.033000 year average in the 'Drug Manufacturers Specialty & Generic' industry
Compound Average Growth Rate 5 Years
Compound Average Growth Rate 5 Years: Ipsen SA has raised their dividend 3.71 years in a row. This is below the 12.576000 year average in the 'Drug Manufacturers Specialty & Generic' industry
Compound Average Growth Rate 10 Years
Compound Average Growth Rate 10 Years: Ipsen SA has raised their dividend 4.14 years in a row. This is below the 10.158800 year average in the 'Drug Manufacturers Specialty & Generic' industry
Payout Ratio
Payout Ratio: Ipsen SA has raised their dividend 15.09 years in a row. This is below the 147.849600 year average in the 'Drug Manufacturers Specialty & Generic' industry